Latest Biotech News

Researchers developed a biomimetic mRNA delivery platform that restores PTEN expression in colorectal tumor models and enhances anti‑tumor immune responses. The system uses targeted delivery...

Chiba University researchers published preclinical results for a cationic nanogel intranasal therapeutic vaccine targeting HPV16 E7 oncoprotein in Science Translational Medicine. The cCHP‑E7 +...

Scientists at Hebrew University and Believer Meats reported a Nature paper describing a non‑genetically modified method to immortalize bovine cells by activating telomerase and PGC1α pathways. The...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD‑388, a late‑stage long‑acting antiviral being developed as seasonal influenza prophylaxis. Cidara’s CD‑388, a drug‑Fc...

Pfizer completed an acquisition of Metsera valued at up to $10 billion to broaden its obesity and metabolic portfolio, securing both a long‑acting GLP‑1 asset and a fast‑acting amylin analog. The...

The U.S. Food and Drug Administration approved ziftomenib (Komzifti) from Kura Oncology and Kyowa Kirin to treat relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutations. The...

Bristol Myers Squibb and Johnson & Johnson halted a phase III trial of their factor XIa inhibitor milvexian in acute coronary syndrome after an interim analysis showed the drug was unlikely to...

Lundbeck submitted an unsolicited, higher cash plus contingent‑value offer for Avadel Pharmaceuticals, complicating Alkermes’ previously announced $2.1 billion takeover agreement. Lundbeck’s...

Medicxi secured €500 million for Fund V to back asset‑centric biotech companies across Europe and select opportunistic later‑stage investments. The raise follows Medicxi’s track record of creating...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of five new products, among them a gene therapy for Wiskott‑Aldrich syndrome developed by...

Researchers unveiled two AI advances: DeepTarget, a deep‑learning platform that predicts anti‑cancer mechanisms of small molecules and potential targets, and CarbaDetector, a machine‑learning...

Researchers at Hebrew University and Believer Meats reported a non‑genetically modified method to induce stable, self‑renewing bovine cell lines by activating telomerase and PGC1α, enabling...

Researchers reported that a gene‑edited pig kidney functioned in a brain‑dead human recipient for 61 days, with multi‑omic and physiological monitoring documenting graft performance and host...

Merck agreed to acquire Cidara Therapeutics for $9.2 billion to secure CD388, a late‑stage, long‑acting antiviral candidate for seasonal influenza. The deal, announced by Merck, pays a substantial...

Pfizer completed its acquisition of Metsera for up to $10 billion, securing the biotech’s obesity assets including a long‑acting GLP‑1 and a fast‑acting amylin analog. The deal closes a...

The U.S. Food and Drug Administration approved ziftomenib (Komzifti) from Kura Oncology and Kyowa Kirin to treat relapsed or refractory acute myeloid leukemia with NPM1 mutations. The approval was...

Bristol Myers Squibb and Johnson & Johnson halted one of three Phase III trials of milvexian, a selective factor XIa inhibitor, after an interim analysis showed futility for the acute coronary...

Lundbeck submitted an unsolicited higher cash offer for Avadel Pharmaceuticals, challenging a prior agreement between Avadel and Alkermes and igniting a bidding war over Lumryz, a marketed...

The U.S. FDA revised the label for Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys, adding a boxed safety warning and limiting use to ambulatory patients, and requested...

European venture firm Medicxi closed a €500 million Fund V to back asset‑centric biotechnology companies and opportunistic later‑stage investments. The oversubscribed fund continues Medicxi’s...